DX
Disease Management, Mechanisms, and Treatment (Platform/Oral)
Friday, May 29, 2015: 2:00 PM-4:00 PM
White River F
2:00 PM
The Effect of Daclizumab High-Yield Process (DAC HYP) on Patient-Centered Functional Outcomes: Results from the DECIDE Study
Michael Kaufman, MD, Cole Neurological Institute, University of Tennessee - Knoxville;
Ludwig Kappos, MD, PhD, University Hospital Basel;
Krzysztof W Selmaj, MD, PhD, Medical Academy of Lodz;
Douglas L Arnold, MD, McGill University;
Eva Havrdova, MD, PhD, Charles University in Prague;
Alexey N Boyko, MD, Usupov Hospital;
Heinz Wiendl, MD, University of Munster;
John Rose, MD, Department of Neurology University of Utah and Neurovirology Research Laboratory VASLCHCS, Imaging and Neuroscience Center;
Steven J Greenberg, MD, AbbVie Biotherapeutics Inc.;
Marianne T. Sweetser, MD, PhD, Biogen Idec, Inc.;
Wei Ma, PhD, Biogen Idec, Inc.;
Ping Wang, PhD, Biogen Idec, Inc.;
Mark Beatty, MD, Biogen Idec
2:20 PM
Current Marijuana Usage By MS Status and Disability in the Narcoms Registry
Stacey S Cofield, PhD, University of Alabama at Birmingham;
Amber R Salter, MPH, University of Alabama at Birmingham;
Tuula Tyry, PhD, Dignity Health, St. Joseph's Hospital and Medical Center;
Sandre McNeal, MS, University of Alabama at Birmingham;
Gary Cutter, PhD, University of Alabama at Birmingham;
Ruth Ann Marrie, MD, PhD, University of Manitoba;
Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
2:40 PM
Alemtuzumab (ALE) Improves Disability after Switch from Other Disease Modifying Therapies in a High Disability Treatment-Refractory Relapsing MS Cohort
Samuel F Hunter, MD, PhD, NeuroNexus Center - Novel Pharmaceutics Institute;
Isabelle St Clare-Hunter, BS, NeuroNexus Center - Novel Pharmaceutics Institute;
Justin M Amburgey, BS, Advanced Neurosciences Institute;
Gregory J Dick, BA, Advanced Neurosciences Institute;
Kristen B Sherman, MS, PA-C, Advanced Neurosciences Institute;
Madelyn B Rarick, BSN, Advanced Neurosciences Institute;
Daniel Kantor, MD, NeuroNexus Center - Novel Pharmaceutics Institute
3:00 PM
Durable Effect of Alemtuzumab on MRI Activity and Brain Atrophy in Relapsing-Remitting Multiple Sclerosis Patients: 4-Year Follow-up of Care-MS II
Anthony Traboulsee, MD, The University of British Columbia;
Hans-Peter Hartung, MD, FRCP, FAAN, FANA, Heinrich-Heine-University Düsseldorf;
Eva Havrdova, MD, PhD, First Faculty of Medicine and General University Hospital, Charles University in Prague;
Krzysztof W Selmaj, MD, PhD, Medical Academy of Lodz;
D Alastair S Compston, MD, University of Cambridge School of Clinical Medicine;
David H Margolin, MD, PhD, Sanofi Genzyme;
Linda Kasten, MA, PROMETRIKA, LLC;
Douglas L Arnold, MD, McGill University
